Midregional Pro-A-Type Natriuretic Peptide for Diagnosis and Prognosis in Patients With Suspected Acute Myocardial Infarction

被引:12
|
作者
Meune, Christophe [1 ,3 ]
Twerenbold, Raphael [1 ,2 ]
Drexler, Beatrice [1 ,2 ]
Balmelli, Cathrin [1 ]
Wolf, Claudia [1 ,2 ]
Haaf, Philip [1 ,2 ]
Reichlin, Tobias [1 ,2 ]
Irfan, Affan [1 ]
Reiter, Miriam [1 ,2 ]
Zellweger, Christa [1 ,2 ]
Meissner, Julia [1 ]
Stelzig, Claudia [1 ]
Freese, Michael [1 ]
Capodarve, Isabel [4 ,5 ]
Mueller, Christian [1 ,2 ]
机构
[1] Univ Basel Hosp, Dept Internal Med, CH-4031 Basel, Switzerland
[2] Univ Basel Hosp, Dept Cardiol, CH-4031 Basel, Switzerland
[3] Paris Descartes Univ, Cochin Hosp, APHP, Dept Cardiol, Paris, France
[4] UPF, CIBERES, ISC 3, Hosp del Mar IMIM,Serv Pneumol, Barcelona, Spain
[5] Hosp del Mar IMIM, Serv Urgencias, Barcelona, Spain
来源
AMERICAN JOURNAL OF CARDIOLOGY | 2012年 / 109卷 / 08期
基金
瑞士国家科学基金会;
关键词
ACUTE CORONARY SYNDROME; TIMI RISK SCORE; CHEST-PAIN POPULATION; ST-SEGMENT ELEVATION; LONG-TERM SURVIVAL; EMERGENCY-DEPARTMENT; STRATIFICATION; ISCHEMIA; PLASMA; BIOMARKERS;
D O I
10.1016/j.amjcard.2011.11.047
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
We hypothesized that midregional pro-A-type natriuretic peptide (MR-proANP), the stable midregional epitope of proANP, might be useful in the early diagnosis and risk stratification of patients with suspected acute myocardial infarction (AMI). In this multi-center study we measured MR-proANP, cardiac troponin T (cTnT), and high-sensitive cTnT (hs-cTnT) at presentation in 675 consecutive patients presenting to the emergency department with suspected AMI. The final diagnosis was adjudicated by 2 independent cardiologists. Patients were followed 360 days for mortality and AMI. AMI was the final diagnosis in 119 patients (18%). Median MR-proANP levels at presentation were significantly higher in patients with AMI (189 pmol/L, interquartile range 97 to 341) versus patients with another final diagnosis (83 pmol/L, 49 to 144, p < 0.001). However, neither the combination of MR-proANP with cTnT nor its combination with hs-cTnT significantly improved diagnostic accuracy as quantified by area under the receiver operating characteristic curve (0.91 vs 0.89 for cTnT alone, p = 0.086; 0.95 vs 0.96 for hs-cTnT, respectively, p = 0.02). Cumulative 360-day mortality/AMI rates were 2.4% in the first, 3.6% in the second, 9.5% in the third, and 18.8% in the fourth quartiles of MR-proANP (p < 0.001). MR-proANP (area under the curve 0.76) predicted mortality/AMI independently of and more accurately than cTnT (area under the curve 0.62), hs-cTnT (area under the curve 0.71), and Thrombolysis In Myocardial Infarction risk score (area under the curve 0.72). Net reclassification improvements offered by the additional use of MR-proANP were 0.388 (p < 0.001), 0.425 (p < 0.001), and 0.217 (p = 0.007), respectively. In conclusion, MR-proANP improves risk prediction for 360-day mortality/AMI but does not seem to help in the early diagnosis of AMI. (C) 2012 Elsevier Inc. All rights reserved. (Am J Cardiol 2012; 109:1117-1123)
引用
收藏
页码:1117 / 1123
页数:7
相关论文
共 50 条
  • [1] Midregional pro-A-type natriuretic peptide for diagnosis and prognosis in patients with suspected acute myocardial infarction
    Meune, C.
    Drexler, B.
    Haaf, P.
    Reichlin, T.
    Reiter, M.
    Meissner, J.
    Stelzig, C.
    Freese, M.
    Winkler, K.
    Mueller, C.
    EUROPEAN HEART JOURNAL, 2011, 32 : 689 - 689
  • [2] Midregional pro-A-type natriuretic peptide for diagnosis and prognosis in patients with suspected acute myocardial infarction
    Meune, C.
    Drexler, B.
    Haaf, P.
    Reichlin, T.
    Reiter, M.
    Meissner, J.
    Stelzig, C.
    Freese, M.
    Winkler, K.
    Mueller, C.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2011, 183 : 689 - 689
  • [3] Midregional pro-A-type natriuretic peptide for the evaluation of exercise intolerance
    Maeder, Micha T.
    Brutsche, Martin H.
    Christ, Andreas
    Staub, Daniel
    Noveanu, Markus
    Breidthardt, Tobias
    Schaub, Nora
    Potocki, Mihael
    Reichlin, Tobias
    Morgenthaler, Nils G.
    Bergmann, Andreas
    Mueller, Christian
    INTERNATIONAL JOURNAL OF CARDIOLOGY, 2010, 145 (02) : 326 - 328
  • [4] Midregional pro-A-type natriuretic peptide and carboxy-terminal provasopressin may predict prognosis in community-acquired pneumonia
    Masia, Mar
    Papassotiriou, Jana
    Morgenthaler, Nils G.
    Hernandez, Ildefonso
    Shum, Conrado
    Gutierrez, Felix
    CLINICAL CHEMISTRY, 2007, 53 (12) : 2193 - 2201
  • [5] Comparison of Midregional Pro-A-Type Natriuretic Peptide and the N-Terminal Pro-B-Type Natriuretic Peptide for Predicting Mortality and Cardiovascular Events
    van Hateren, Kornelis J. J.
    Alkhalaf, Alaa
    Kleefstra, Nanne
    Groenier, Klaas H.
    de Jong, Paul E.
    de Zeeuw, Dick
    Gans, Rijk O. B.
    Struck, Joachim
    Bilo, Henk J. G.
    Gansevoort, Ron T.
    Bakker, Stephan J. L.
    CLINICAL CHEMISTRY, 2012, 58 (01) : 293 - 297
  • [6] Midregional pro-A-type natriuretic peptide measurements for diagnosis of acute destabilized heart failure in short-of-breath patients: Comparison with B-type natriuretic peptide (BNP) and amino-terminal proBNP
    Gegenhuber, A
    Struck, J
    Poelz, W
    Pacher, R
    Morgenthaler, NG
    Bergmann, A
    Haltmayer, M
    Mueller, T
    CLINICAL CHEMISTRY, 2006, 52 (05) : 827 - 831
  • [7] Midregional Pro-A-Type Natriuretic Peptide as Part of a Dual Biomarker Strategy for the Early Rule Out of Non-ST Segment Myocardial Infarction - WilCop Study
    Tajsic, Milos
    Jarai, Rudolf
    Schwarz, Michael A.
    Kitzbrecht, Juergen
    Koch, Johannes
    Wojta, Johann
    Huber, Kurt
    CIRCULATION, 2013, 128 (22)
  • [8] N-terminal pro b-type natriuretic peptide in the early diagnosis and risk stratification of suspected acute myocardial infarction
    Haaf, P.
    Balmelli, C.
    Reichlin, T.
    Twerenbold, R.
    Reiter, M.
    Meissner, J.
    Meune, C.
    Drexler, B.
    Osswald, S.
    Mueller, C.
    EUROPEAN HEART JOURNAL, 2011, 32 : 991 - 991
  • [9] Prognostic Value of Midregional Pro-A-Type Natriuretic Peptide and N-Terminal Pro-B-Type Natriuretic Peptide in Patients with Stable Coronary Heart Disease Followed over 8 Years
    Karakas, Mahir
    Jaensch, Andrea
    Breitling, Lutz P.
    Brenner, Hermann
    Koenig, Wolfgang
    Rothenbacher, Dietrich
    CLINICAL CHEMISTRY, 2014, 60 (11) : 1441 - 1449
  • [10] Direct comparison of B-type natriuretic peptide and midregional pro-atrial natriuretic peptide in the diagnosis of acute heart failure
    Krivoshei, L.
    Twerenbold, R.
    Weidmann, Z. Moreno
    Wildi, K.
    Pershyna, K.
    Stallone, F.
    Herrmann, T.
    Osswald, S.
    Mueller, C.
    EUROPEAN HEART JOURNAL, 2014, 35 : 861 - 861